Company Overview

ViewRay® Inc., (NASDAQ:VRAY), designs, manufactures and markets MRIdian® the world’s first MRI-guided radiation therapy system that can image and treat cancer patients simultaneously. MRIdian addresses key limitations of existing external-beam radiation therapy technologies because it integrates MRI technology, radiation delivery, and proprietary software to locate, target, and track the position and shape of soft-tissue tumors while radiation is delivered. Real-time MRI-imaging clearly defines the targeted tumor from the surrounding soft tissue and other critical organs during radiation treatment allowing the system to deliver radiation to the tumor accurately while delivering less radiation to healthy tissue. MRIdian’s targeting accuracy combined with improved tumor visibility and accurate dose recording means clinicians can treat patients who may not previously have been considered radiation therapy candidates. ViewRay believes MRIdian may improve the safety and efficacy of radiation therapy, potentially leading to improved patient outcomes with reduced side-effects from off-target radiation delivery.

Financial News

Date Title and Summary Additional Formats
Toggle Summary ViewRay Announces Conference Call and Webcast of Fourth Quarter and Full Year 2018 Financial Results to be Held After Market on March 14, 2019
CLEVELAND , Feb. 14, 2019 /PRNewswire/ --  ViewRay, Inc. (Nasdaq: VRAY) announced today details relating to the release of its fourth quarter and full year 2018 financial results. ViewRay will hold a conference call to discuss results on Thursday March 14, 2019 at 4:30 p.m. ET / 1:30 p.m. PT .
Toggle Summary World's First MRIdian Center Celebrates Five Years of MRI-Guided Radiation Treatments
Siteman Cancer Center Advances Precision Cancer Care through Presentations, Peer-Reviewed Publications and Pioneering Clinical Experience on its MRIdian Systems CLEVELAND , Jan. 22, 2019 /PRNewswire/ --  ViewRay, Inc. (Nasdaq: VRAY) announced today the five-year anniversary of patient treatments
Toggle Summary ViewRay Announces Preliminary Fourth Quarter and Fiscal Year 2018 Results
CLEVELAND , Jan. 7, 2019 /PRNewswire/ --  ViewRay, Inc. (Nasdaq: VRAY) today announced preliminary results for the fourth quarter and full fiscal year ended December 31, 2018 . The preliminary results have not been audited and are subject to change. Selected Fourth Quarter and Full Year 2018
Toggle Summary ViewRay Announces First Patient Enrolled in Stereotactic MRI-guided On-table Adaptive Radiation Therapy (SMART) Trial for Locally Advanced Pancreatic Cancer
Study to Explore Clinical Benefits of Precise, High Dose Radiation Therapy Enabled by MRIdian's MR-guidance Combined with Daily On-table Adaptation in Pancreatic Cancer CLEVELAND , Jan. 4, 2019 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today the enrollment of the first patient in the

Stock Quote

Copyright West LLC. Minimum 15 minutes delayed.

Featured Items

E-mail Alerts

Alerts are e-mailed to you whenever certain new company information is posted to this site. Sign-up Now!
Click here for E-mail Alerts

Transfer Agent
American Stock Transfer & Trust Company, LLC
6201 15th Avenue
Brooklyn, NY 11219
(800) 937-5449
Website: www.amstock.com
Email: info@amstock.com

In Need of Customer Support? Contact

  Language Select